Tacrolimus but not cyclosporine A enhances FGF-2-induced VEGF release in osteoblasts

  • Authors:
    • Junichi Yamauchi
    • Shinji Takai
    • Rie Matsushima-Nishiwaki
    • Seiji Adachi
    • Chiho Minamitani
    • Hideo Natsume
    • Jun Mizutani
    • Takanobu Otsuka
    • Jun Takeda
    • Atsushi Harada
    • Osamu Kozawa
    • Haruhiko Tokuda
  • View Affiliations

  • Published online on: February 1, 2009     https://doi.org/10.3892/ijmm_00000126
  • Pages: 267-272
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We previously reported that basic fibroblast growth factor (FGF-2) stimulates the release of vascular endothelial growth factor (VEGF) via p44/p42 mitogen-activated protein (MAP) kinase and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in osteoblast-like MC3T3-E1 cells and that FGF-2-activated p38 MAP kinase negatively regulates VEGF release. In addition, p70 S6 kinase activated by FGF-2 negatively regulates VEGF release via SAPK/JNK. In the present study, we investigated the effects of tacrolimus (FK506) and cyclosporine A, well-known immunosuppressants, on the FGF-2-induced VEGF release in these cells. Tacrolimus, but not cyclosporine A which alone had no effect on VEGF basal levels, significantly enhanced FGF-2-stimulated VEGF release. Tacrolimus markedly enhanced FGF-2-induced phosphorylation of SAPK/JNK without affecting the phosphorylation of p44/p42 MAP or p38 MAP kinases. SP600125, a specific inhibitor of SAPK/JNK, reduced the amplification by tacrolimus of the FGF-2-induced VEGF release. The FGF-2-induced phosphorylation of p70 S6 kinase was suppressed by tacrolimus. These results strongly suggest that tacrolimus enhances FGF-2-stimulated VEGF release via up-regulation of SAPK/JNK through modulating p70 S6 kinase in osteoblasts.

Related Articles

Journal Cover

February 2009
Volume 23 Issue 2

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yamauchi J, Takai S, Matsushima-Nishiwaki R, Adachi S, Minamitani C, Natsume H, Mizutani J, Otsuka T, Takeda J, Harada A, Harada A, et al: Tacrolimus but not cyclosporine A enhances FGF-2-induced VEGF release in osteoblasts. Int J Mol Med 23: 267-272, 2009.
APA
Yamauchi, J., Takai, S., Matsushima-Nishiwaki, R., Adachi, S., Minamitani, C., Natsume, H. ... Tokuda, H. (2009). Tacrolimus but not cyclosporine A enhances FGF-2-induced VEGF release in osteoblasts. International Journal of Molecular Medicine, 23, 267-272. https://doi.org/10.3892/ijmm_00000126
MLA
Yamauchi, J., Takai, S., Matsushima-Nishiwaki, R., Adachi, S., Minamitani, C., Natsume, H., Mizutani, J., Otsuka, T., Takeda, J., Harada, A., Kozawa, O., Tokuda, H."Tacrolimus but not cyclosporine A enhances FGF-2-induced VEGF release in osteoblasts". International Journal of Molecular Medicine 23.2 (2009): 267-272.
Chicago
Yamauchi, J., Takai, S., Matsushima-Nishiwaki, R., Adachi, S., Minamitani, C., Natsume, H., Mizutani, J., Otsuka, T., Takeda, J., Harada, A., Kozawa, O., Tokuda, H."Tacrolimus but not cyclosporine A enhances FGF-2-induced VEGF release in osteoblasts". International Journal of Molecular Medicine 23, no. 2 (2009): 267-272. https://doi.org/10.3892/ijmm_00000126